不可切除的腹膜粘液癌的肠和多内脏移植 (TRANSCAPE) (TRANSCAPE)
不可切除的腹膜粘液癌肠和多脏器移植前瞻性病例系列 (TRANSCAPE)
The goal of this prospective phase 2 study is to assess the efficacy and safety of intestinal or multivisceral transplantation for participants with PMP not amenable to other curative-intent treatments. Participants will undergo intestinal/multivisceral transplantation. Participants will be followed for 12 months to assess efficacy and safety.
研究概览
地位
详细说明
Pseudomyxoma peritonei (PMP) is a rare clinical entity (approximately 2-4 cases per million people) characterized by extensive dissemination of mucinous ascites in the abdominal cavity. Relentless accumulation of mucin causes progressive abdominal distention, intestinal obstruction, malnutrition, cachexia, and ultimately death. As a rare disease, diagnosis is often late, and usually occurs when the disease is in a clinically advanced stage. The prognosis of PMP has been dramatically improved by the introduction of cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC). While outcomes are favorable for participants with disease amenable to CRS+HIPEC, the therapeutic options for participants with unresectable PMP are limited. Intestinal transplantation represents a therapeutic option in participants with unresectable PMP. Overall survival has been shown to improve with participants with unresectable PMP during an Oxford Transplant Center study. The goal of this study is to corroborate the Oxford results on an American cohort.
研究类型
注册 (估计的)
阶段
- 阶段2
联系人和位置
学习联系方式
- 姓名:Masato Fujiki, MD, PhD
- 电话号码:216-444-8007
- 邮箱:fujikim@ccf.org
学习地点
-
-
Ohio
-
Cleveland、Ohio、美国、44195
- Cleveland Clinic Digestive Disease & Surgery Institute (DDSI), Case Comprehensive Cancer Center
-
接触:
- Masato Fujiki, MD, PhD
- 电话号码:216-444-8007
- 邮箱:fujikim@ccf.org
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Inclusion Criteria:
-
Subjects must have histologically confirmed pseudomyxoma peritonei (PMP)
- Both low-grade mucinous carcinoma peritonei (LMCP) or high-grade mucinous carcinoma (HMCP), with or without signet ring cells as well as primary or recurrent disease, will be eligible.
-
PMP disease does not have any extra-abdominal metastases, with the exception of pulmonary involvement (nodal, parenchymal, and pleural).
-
PMP disease is extensive and not amenable to operative management, with or without liver, pancreas, stomach, or abdominal wall involvement.
-
Definition of Non-Resectable Disease-
-
Non-resectable PMP disease will be defined as the presence of at least one of the following conditions:
- 1) Extensive small bowel serosa involvement, where it is not possible to preserve at least 1.5-2 m of small bowel
- 2) Extensive infiltration of the pancreatic surface
- 3) Mesenteric involvement causing retraction
- 4) Need for complete gastric resection
- 5) Urete1ic obstruction
- 6) Liver disease with no chance to achieve R0 resection with liver remnant volume > 30%
- 7) Recurrent disease not amenable to further resection
-
-
-
Subjects do not have any other available curative treatment options.
- Subjects can have previous abdominal operations, including CRS+HIPEC.
-
Age ≥ 18 and ≤ 75.
- Pediatric participants were excluded as PMP is a disease that affects adults. Participants > 75 years of age are excluded as they are beyond the commonly accepted transplantability criteria.
-
Performance status ECOG ≤ 1.
-
Subjects must have the ability to understand and the willingness to sign a written informed consent document.
Exclusion Criteria:
- Subjects with peritoneal carcinomatous originating from an etiology other than PMP.
- Subjects receiving any other investigational agents.
- Subjects with uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would either put participation at risk because of participation in the study, may influence the result of the study, or limit compliance with study requirements.
- Pregnant women are excluded from this study because an intestinal transplant is a procedure that is not compatible with a viable pregnancy.
- Subjects who are HIV-positive may be included in the study. HIV testing is required for the study as adequate HIV treatment is required prior to intestinal transplant due to the increased risk of infection following transplantation and treatment with immunosuppressive agents.
学习计划
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:不适用
- 介入模型:单组作业
- 屏蔽:无(打开标签)
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
实验性的:Intestinal, Multivisceral or Modified Multivisceral Transplantation
Participants will undergo intestinal or modified multivisceral transplantation according to their disease extent. Participants will be followed for 12 months from the day of transplantation. Participants will undergo routine clinical follow-up according to standard protocols for the management of participants after visceral organ transplantation and standard oncological follow-up for participants with PMP. |
Enrolled participants will enter the active transplant waiting list within one month of signing informed consent for study participation. Participants can be listed for:
A post-transplant, steroid-free immunosuppressive regimen will be utilized and will include Alemtuzumab as Antibody Induction Therapy. Participants will be administered two doses of Alemtuzumab (30 mg IV) on days 0 and 1. A post-transplant, steroid-free immunosuppressive regimen will be utilized and will include Tacrolimus for maintenance. Participants will have Tacrolimus for the first 3 months. Dosing of Tacrolimus will depend on participant target level, starting with 0.05 mg/Kg bid. A post-transplant, steroid-free immunosuppressive regimen will be utilized and will include Sirolimus for maintenance. Participants will have Sirolimus after 3 months of Tacrolimus. Dosing of Sirolimus will depend on participant target level, starting with 2 mg od. |
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Overall Rate of Survival
大体时间:12 months post operative
|
To determine overall 12-month survival after intestinal or multivisceral transplantation in participants with unresectable PMP. |
12 months post operative
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Overall Rate of Morbidity
大体时间:90 days post operative
|
Determine the morbidity of intestinal or multivisceral transplantation for participants with unresectable at 90 days by monitoring severe adverse events as classified according to Clavien-Dindo grade and comprehensive complication index. |
90 days post operative
|
|
Overall Rate of Morbidity
大体时间:12 months post operative
|
Determine the morbidity of intestinal or multivisceral transplantation for participants with unresectable at 12 months by monitoring severe adverse events as classified according to Clavien-Dindo grade and comprehensive complication index. |
12 months post operative
|
|
Overall Rate of Mortality
大体时间:12 months post operative
|
Determine cancer-related and transplant-related mortality after intestinal or multivisceral transplantation in participants with unresectable PMP. |
12 months post operative
|
合作者和调查者
调查人员
- 首席研究员:Masato Fujiki, MD, PhD、Cleveland Clinic Digestive Disease & Surgery Institute (DDSI) , Case Comprehensive Cancer Center
研究记录日期
研究主要日期
学习开始 (估计的)
初级完成 (估计的)
研究完成 (估计的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
与本研究相关的术语
关键字
其他相关的 MeSH 术语
其他研究编号
- CASE7Z23
计划个人参与者数据 (IPD)
计划共享个人参与者数据 (IPD)?
IPD 计划说明
As an investigator-initiated protocol, individual participant data will not need to be shared with any other third party. Reported results from this trial will be aggregated data.
药物和器械信息、研究文件
研究美国 FDA 监管的药品
研究美国 FDA 监管的设备产品
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.